Genomic Health, Inc. (MM) (NASDAQ:GHDX)
Historical Stock Chart
5 Years : From May 2012 to May 2017
Top Food and Drug Administration officials suggested they would set a high, if not impossible, bar for companies seeking to sell genetic tests directly to consumers.
In an interview, Jeffrey Shuren, head of FDA's medical-devices division, and Alberto Gutierrez, who oversees the FDA unit that regulates certain laboratory tests, said they considered direct-to-consumer genetic tests "high risk" and have already informed companies selling such tests through their websites that they must seek FDA approval.
Although the FDA hasn't ordered existing tests off the market, Shuren suggested it could be difficult to gain agency approval. The agency is convening a two-day public hearing starting Monday to discuss how it would regulate diagnostic tests, including direct-to-consumer tests.
Shuren said he was concerned about cutting doctors out of the process of interpreting laboratory tests and afraid consumers could make risky medical decisions based on information that suggests they are at risk of developing cancer, diabetes or other diseases or could stop taking a needed medication.
The issue came to light in May after Pathway Genomics Corp., a closely held firm based in San Diego, announced plans to sell its Insight Saliva Collection Kit through Walgreen Co. (WAG) and CVS Caremark Corp (CVS). Both retailers backed out of plans to sell the test after the FDA raised concerns.
The Insight Saliva and similar tests such as ones sold by other California firms, 23andMe Inc. and Navigenics Inc., are designed to predict a person's risk for developing certain diseases or how they might respond to certain drugs. They can also be used to predict the risk of certain diseases caused by recessive genes that might be passed to a child from parents.
Shuren noted that the FDA has so far declined to approve an over-the-counter HIV test partly on concerns that test results would be first seen by a consumer and not a doctor.
"The question is what's the benefit to consumers," Shuren said.
Pathway recently changed course and now requires its test to be ordered through a physician.
Traditionally, FDA has regulated laboratory tests that are sold to hospitals and doctor's offices along with over-the-counter tests like blood glucose test strips, but it hasn't required approval for so-called laboratory-developed tests that fall under a system regulated by the Centers for Medicare and Medicaid Services.
CMS certifies laboratories, but if a test is analyzed in the same lab, it traditionally hasn't required FDA approval because such tests were considered low-risk and easy to understand.
But now that such laboratory-developed tests can predict a person's risk for cancer recurrence or the risk of developing other diseases, FDA officials say those should go through the FDA-approval process.
The move will affect several other companies including Quest Diagnostics (DCX) and Laboratory Corporation of America (LH), or LabCor, and Genomic Health Inc. (GHDX), which sells a test that's well regarded in the medical community for predicting the risk of breast-cancer recurrence.
The American Clinical Laboratory Association, which represents laboratories, said it believes that current regulations do need to be updated, but said it was concerned that if current FDA medical-device regulations are applied to lab tests that it might impede the development of "cutting edge tests."
-By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294; email@example.com